© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
December 02, 2021
Base on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.
December 01, 2021
Zai Lab has announced new findings from the phase 3 PRIME trial showing efficacy in progression-free survival in patients with platinum-sensitive ovarian cancer.
The combination elicited a complete response in patient with cervical cancer and a partial response in a patient with ovarian cancer.
Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.
The FDA has decided not to approve plinabulin with granulocyte colony-stimulating factor for the prevention of chemotherapy-induce neutropenia until further research is conducted.
Thomas Powles, MD, MBBS, MRCP, discusses the safety profile of enfortumab vedotin in urothelial cancers as observed in the phase 3 urothelial cancerstrial.
The approval is based on the phase 2 PLEAIDES study, which found the agent had an ORR of 84.8%, with 82.5% of patients still responding after 9 months.
In an interview with Targeted Oncology, Richard M. Stone, MD, discussed challenging subtypes of acute myeloid leukemia and therapies available to treat them.
Here is a look back FDA happenings from November 2021.
A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma.
Next steps investigating novel-based therapies for newly diagnosed metastatic renal cell carcinoma.
Advice to oncology nurses who manage patients with metastatic renal cell carcinoma receiving novel-based therapies, including lenvatinib and pembrolizumab.